Abstract OE-1
URINARY EXOSOMAL BIOMARKERS IN THYROID CANCER PATIENTS WITH ABLATIVE THERAPY: A PILOT STUDY 1
TSE-YING HUANG, 2,3CHIH-YUAN WANG, 2LI-TING HUANG, 2YI-CHIEH CHUNG
1
Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Taiwan; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taiwan; 3 Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch,Taiwan
Background: Although thyroid cancers are low-grade endocrine malignancy, most patients usually received thyroidectomy with ablative radioactive iodine therapy. Such patients were followed with thyroid ultrasonography and serial serum thyroglobulin evaluation. Methods: Exosomes are nanovesicles secreted into extracellular environments. Cancer cellderived exosomes could be found in plasma, saliva, urine and other body fluid of patients with cancer. We try to analyze the urinary exosomal proteins, including thyroglobulin and galectin-3, to find the early prognostic biological markers in urine via this prospective study. Results: The trends of urinary thyroglobulin concentrations in patients with post-ablative thyroid cancer were detected in the very first three patients. Importantly, serum thyroglobulin cannot be found in two patients after radioactive I-131 ablation, however, urinary exosomal thyroglobulin still showed an increasing trend. Conclusions: Since expensive recombinant human TSH (rhTSH) is usually needed to stimulate serum thyroglobulin for detecting local recurrence or distant metastasis. The issue of earlier biological markers for predicting prognosis of thyroid cancer should be raised. This pilot study report is the very first one to explore that urinary exosomal thyroglobulin could be a reliable biological marker to substitute for serum thyroglobulin in the future.
105
